Nowadays, in the clinic routine, protein biomarkers of efficacy, or mode of action, are
used to better monitor and predict patient responses to drug treatment and diagnosis.
Currently, the chemiluminescence biomarkers are applied for validation methods and
screening. Here, was revised the development of the new analytical tool through
immunological (antibody) and chemiluminescent methods combination, named
chemiluminescence immunoassay (CLIA). In the tumoral process, increased
expression of specific antigens is associated in patients with certain tumors. Thus, in
our laboratories CLIA has been tested to study different tumoral lesions from glandular
tissues, like prostate and thyroid. In conclusion, there is a great opportunity for
introducing the adaptive chemiluminescence devices, since clinical diagnostics
represents a huge, well-established and important analytical field.
 
Nowadays, in the clinic routine, protein biomarkers of efficacy, or mode of action, are
used to better monitor and predict patient responses to drug treatment and diagnosis.
Currently, the chemiluminescence biomarkers are applied for validation methods and
screening. Here, was revised the development of the new analytical tool through
immunological (antibody) and chemiluminescent methods combination, named
chemiluminescence immunoassay (CLIA). In the tumoral process, increased
expression of specific antigens is associated in patients with certain tumors. Thus, in
our laboratories CLIA has been tested to study different tumoral lesions from glandular
tissues, like prostate and thyroid. In conclusion, there is a great opportunity for
introducing the adaptive chemiluminescence devices, since clinical diagnostics
represents a huge, well-established and important analytical field.
การแปล กรุณารอสักครู่..
